Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
PF-06882961 Tris
Cat. No.:
OB0225LY-0267
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR, HPLC, and LC-MS.
Size:
Product Overview
Description:
PF-06882961 Tris is a small molecule compound with significant GLP-1 receptor agonism that enhances insulin secretion and improves glucose metabolism.
Synonym:
2230198-03-3; Danuglipron tromethamine; 2-((4-(6-(4-Cyano-2-fluorobenzyloxy)pyridin-2-yl)piperidin-1-yl)methyl)-1-((2S)-oxetan-2-ylmethyl)-1H-benzimidazole-6-carboxylic acid, (1:1) salt with 2-amino-2-(hydroxymethyl)propane-1,3-diol; 2-Amino-2-(hydroxymethyl)propane-1,3-diol 2-[[4-[6-[(4-cyano-2-fluorophenyl)methoxy]pyridin-2-yl]piperidin-1-yl]methyl]-3-[[(2S)-oxetan-2-yl]methyl]benzimidazole-5-carboxylic acid
CAS No.:
2230198-03-3
Compound CID:
154702463
Formula:
C35H41FN6O7
Formula Weight:
676.7
Specification
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
PF-06882961 Tris can be used to study diabetes-related signaling pathways or play an important role in the development of new drugs with a special focus on the mechanisms of insulin regulation.
Library Information
Targets:
Glucagon receptor
Receptors:
GLP-1
Pathways:
GPCR/G protein
Plate Number:
AOCL-4
Plate Location:
d6
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10 mM DMSO
DMSO Max Solubility:
45 mg/mL; 66.5 mM
